Mixtard 50 Penfill (Insulin Human)

Insulin Human, the active ingredient in Mixtard 50 Penfill, is an insulin presented as a pre‑filled insulin pen for subcutaneous use. It is used to manage blood glucose levels in patients with diabetes mellitus. GNH USA supplies Mixtard 50 Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mixtard 50 Penfill provides rapid‑acting insulin therapy for diabetes mellitus and related hyperglycaemia. - Type 1 diabetes mellitus: improves glycaemic control by replacing deficient endogenous insulin. - Type 2 diabetes mellitus: assists in achieving target blood glucose when oral agents are insufficient. - Gestational diabetes mellitus (when insulin therapy is required): maintains maternal and fetal glucose homeostasis.

Common Side Effects: - Hypoglycaemia: low blood glucose levels, often presenting with sweating, tremor, or dizziness. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight due to improved glucose utilization. - Lipodystrophy: localized changes in subcutaneous fat at repeated injection sites. - Edema: mild fluid retention, especially in the lower extremities.

Serious or Rare Side Effects: - Severe hypoglycaemia: neurological impairment, seizures, or loss of consciousness. - Allergic reactions: rash, urticaria, or anaphylaxis requiring immediate medical attention. - Insulin antibodies: formation of antibodies that may alter insulin efficacy. - Hypokalemia: low serum potassium levels, potentially leading to cardiac arrhythmias. - Lipohypertrophy: large, firm lumps of fatty tissue that can affect insulin absorption.

Mixtard 50 Penfill requires careful monitoring and patient education to minimise risks. - Blood glucose monitoring: regularly check glucose levels to adjust dosing appropriately. - Hypoglycaemia risk: avoid dosing when blood glucose is already low and educate patients on recognising symptoms. - Concomitant medications: be aware of drugs that may potentiate or mask hypoglycaemia. - Pregnancy and lactation: use only if clearly needed; benefits should outweigh potential risks. - Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Mixtard 50 Penfill may interact with several drug classes, requiring dose adjustments or monitoring. Major Interactions (Avoid): - Beta‑blockers: can mask hypoglycaemia symptoms, increasing risk. - ACE inhibitors: may potentiate insulin’s glucose‑lowering effect. - Thiazide diuretics: can enhance hypoglycaemia. - Alcohol: may cause unpredictable blood glucose fluctuations. - Oral hypoglycaemic agents: additive glucose‑lowering effect, raising hypoglycaemia risk.

Moderate Interactions (Monitor Closely): - Corticosteroids: may increase insulin requirements. - Thyroid hormones: can alter insulin sensitivity. - Growth hormone therapy: may reduce insulin effectiveness. - Lipid‑lowering agents (e.g., fibrates): potential for modest glucose changes. - Certain antibiotics (e.g., fluoroquinolones): may affect blood glucose control.